The arrival of highly effective incretin-based medications has sparked much discussion on social media and throughout traditional media – as well as amongst researchers and clinicians – about whether there is a need to be concerned about muscle loss during the use of GLP-1s and other similar types of medication.
But a presentation from Associate Professor Priya Sumithran, an endocrinologist and from Bayside Health and Monash University, at the recent International Diabetes Federation Western Pacific Region Congress, put this speculation under the microscope to determine if the reported muscle loss is something we truly need to be worried about.
Professor Sumithran began her talk by clarifying some of the terminology used in conversations like these.
“When looking at the literature on body composition, we need to be aware that different techniques measure different things. And [although certain] terminology – such as fat-free mass, lean soft tissue, and skeletal muscle – is often used interchangeably, they actually represent quite different entities,” she told delegates.
